| Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade PJ Johnson, S Berhane, C Kagebayashi, S Satomura, M Teng, ... Journal of Clinical Oncology 33 (6), 550-558, 2015 | 2528 | 2015 |
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952, 2018 | 2374 | 2018 |
| Cabozantinib in patients with advanced and progressing hepatocellular carcinoma GK Abou-Alfa, T Meyer, AL Cheng, AB El-Khoueiry, L Rimassa, BY Ryoo, ... New England Journal of Medicine 379 (1), 54-63, 2018 | 2357 | 2018 |
| Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial RS Finn, BY Ryoo, P Merle, M Kudo, M Bouattour, HY Lim, V Breder, ... Journal of Clinical Oncology 38 (3), 193-202, 2020 | 1643 | 2020 |
| Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma GK Abou-Alfa, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse, ... NEJM evidence 1 (8), EVIDoa2100070, 2022 | 931 | 2022 |
| Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments K Sun, P Jiang, KCA Chan, J Wong, YKY Cheng, RHS Liang, W Chan, ... Proceedings of the National Academy of Sciences 112 (40), E5503-E5512, 2015 | 786 | 2015 |
| Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients P Jiang, CWM Chan, KCA Chan, SH Cheng, J Wong, VWS Wong, ... Proceedings of the National Academy of Sciences 112 (11), E1317-E1325, 2015 | 770 | 2015 |
| Analysis of plasma Epstein–Barr virus DNA to screen for nasopharyngeal cancer KCA Chan, JKS Woo, A King, BCY Zee, WKJ Lam, SL Chan, SWI Chu, ... New England Journal of Medicine 377 (6), 513-522, 2017 | 735 | 2017 |
| Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing KCA Chan, P Jiang, YWL Zheng, GJW Liao, H Sun, J Wong, SSN Siu, ... Clinical chemistry 59 (1), 211-224, 2013 | 640 | 2013 |
| Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma PR Galle, F Foerster, M Kudo, SL Chan, JM Llovet, S Qin, WR Schelman, ... Liver international 39 (12), 2214-2229, 2019 | 549 | 2019 |
| Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers VWS Wong, SL Chan, F Mo, TC Chan, HHF Loong, GLH Wong, YYN Lui, ... Journal of clinical oncology 28 (10), 1660-1665, 2010 | 544 | 2010 |
| Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a … RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ... The Lancet 401 (10391), 1853-1865, 2023 | 535 | 2023 |
| Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing KCA Chan, P Jiang, CWM Chan, K Sun, J Wong, EP Hui, SL Chan, ... Proceedings of the National Academy of Sciences 110 (47), 18761-18768, 2013 | 515 | 2013 |
| Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma AL Cheng, C Hsu, SL Chan, SP Choo, M Kudo Journal of hepatology 72 (2), 307-319, 2020 | 459 | 2020 |
| Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial RK Kelley, L Rimassa, AL Cheng, A Kaseb, S Qin, AX Zhu, SL Chan, ... The Lancet Oncology 23 (8), 995-1008, 2022 | 419 | 2022 |
| High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma HLY Chan, CH Tse, F Mo, J Koh, VWS Wong, GLH Wong, S Lam Chan, ... Journal of Clinical Oncology 26 (2), 177-182, 2008 | 388 | 2008 |
| Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma … GK Abou-Alfa, SL Chan, M Kudo, G Lau, RK Kelley, J Furuse, ... Journal of Clinical Oncology 40 (4_suppl), 379-379, 2022 | 380 | 2022 |
| The concise guide to pharmacology 2017/18: overview SPH Alexander, E Kelly, NV Marrion, JA Peters, E Faccenda, SD Harding, ... British journal of pharmacology 174, S1-S16, 2017 | 373 | 2017 |
| Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study S Qin, SL Chan, S Gu, Y Bai, Z Ren, X Lin, Z Chen, W Jia, Y Jin, Y Guo, ... The Lancet 402 (10408), 1133-1146, 2023 | 372 | 2023 |
| Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial P Schmid, J Abraham, S Chan, D Wheatley, AM Brunt, G Nemsadze, ... Journal of Clinical Oncology 38 (5), 423-433, 2020 | 351 | 2020 |
